(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 September 2011 (01.09.2011)

PCT

(10) International Publication Number
WO 2011/104652 A3

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/00* (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:
PCT/IB2011/050625

(22) International Filing Date:
15 February 2011 (15.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/307,713 24 February 2010 (24.02.2010) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NARISHETTY, Sunil, Thomas, Kumar** [IN/US]; Pfizer Global Research & Development, 7000 Portage Road, Kalamazoo, Michigan 49001 (US). **PRICE, Jeffrey, Ellis** [US/US]; Pfizer Global Research & Development, 7000 Portage Road, Kalamazoo, Michigan 49001 (US). **REPAKULA, Sreenath** [CA/US]; Pfizer Global Research & Development, 7000 Portage Road, Kalamazoo, Michigan 49001 (US).

(74) Agent: **KLEIMAN, Gabriel, L.**; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
10 November 2011

(54) Title: VETERINARY COMPOSITIONS

(57) Abstract: The present invention relates to veterinary compositions in a form of an orally deliverable tablet, and more particularly to a controlled-release composition that provides sufficiently long duration to permit once daily administration.

WO 2011/104652 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2011/050625

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K9/20 A61K9/00 A61K31/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, CHEM ABS Data, EMBASE, WPI Data, BIOSIS, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/035029 A1 (DEPOMED INC [US]) 1 May 2003 (2003-05-01) page 3, line 17 - line 26 page 14, line 24 - page 15, line 16 table 5 claims 1-40	1-5,8-18
X	WO 2004/066981 A1 (SUN PHARMACEUTICAL IND LTD [IN]; DUDHARA KAMLESH MOHANLAL [IN]; DHARMA) 12 August 2004 (2004-08-12) example 1 claims 1-41	1,2,4-7, 11,13, 15-18
X	US 2004/234608 A1 (FLESHNER-BARAK MOSHE [IL] ET AL) 25 November 2004 (2004-11-25) examples	1-7,11, 13-18

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
4 August 2011	12/08/2011

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Schüle, Stefanie

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	WO 2010/020905 A1 (PFIZER [US]; BERLINSKI PAMELA JO [US]; BIRCHMEIER MATTHEW JOSEPH [US];) 25 February 2010 (2010-02-25) the whole document	1-19,21
A	WO 02/00661 A1 (PFIZER PROD INC [US]; BLUMENKOPF TODD ANDREW [US]; FLANAGAN MARK EDWAR) 3 January 2002 (2002-01-03) the whole document	1-19,21
X	WO 2007/052125 A2 (PFIZER PROD INC [US]; BOCKBRADER HOWARD NORMAN [US]; CHO YUN HYUNG [US) 10 May 2007 (2007-05-10) examples 1-11	1-18,20, 22
X	EP 1 681 050 A1 (STRIDES ARCOLAB LTD [IN]) 19 July 2006 (2006-07-19)	1,2,4,8, 11-18,20
Y	examples	1-18,20, 23
Y	WO 2004/073695 A1 (LEK PHARMACEUTICALS [SI]; KERC JANEZ [SI]; OPARA JERNEJA [SI]; JENKO O) 2 September 2004 (2004-09-02) examples	1-18,20, 23
Y	US 2007/154547 A1 (FLANNER HENRY H [US] ET AL) 5 July 2007 (2007-07-05) examples	1-18,20, 23
X	US 2007/020335 A1 (CHEN ANDREW X [US] ET AL) 25 January 2007 (2007-01-25)	1-3,6-9, 11,12, 14-18, 20,24
Y	examples page 1, paragraph 0003	1-18,20, 24
Y	WO 2009/114648 A1 (DEPOMED INC [US]; CHIEN-HSUAN HAN [US]; HOU SUI YUEN EDDIE [US]; REID) 17 September 2009 (2009-09-17) example 6	1-18,20, 24
A	MARTINEZ M N ET AL: "Factors influencing the gastric residence of dosage forms in dogs", JOURNAL OF PHARMACEUTICAL SCIENCES 200903 US LNKD- DOI:10.1002/JPS.21499, vol. 98, no. 3, March 2009 (2009-03), pages 844-860, XP002634719, ISSN: 0022-3549 the whole document	1-21

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2011/050625

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RATHBONE MICHAEL J ET AL: "Modified release drug delivery in veterinary medicine.", DRUG DISCOVERY TODAY, vol. 7, no. 15, 1 August 2002 (2002-08-01) , pages 823-829, XP002634720, ISSN: 1359-6446 the whole document -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IB2011/050625

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03035029 A1	01-05-2003	CA 2409910 A1	25-04-2003
		EP 1439819 A1	28-07-2004
		JP 2005506998 A	10-03-2005
		MX PA04003929 A	29-11-2004
		US 2003091630 A1	15-05-2003
		US 2003133985 A1	17-07-2003
		US 2004156899 A1	12-08-2004
WO 2004066981 A1	12-08-2004	AU 2003230189 A1	23-08-2004
		US 2005163839 A1	28-07-2005
US 2004234608 A1	25-11-2004	US 2010278912 A1	04-11-2010
WO 2010020905 A1	25-02-2010	AR 073073 A1	13-10-2010
		AU 2009283844 A1	25-02-2010
		CA 2733359 A1	25-02-2010
		CN 102131812 A	20-07-2011
		EC SP110904 A	29-04-2011
		KR 20110043697 A	27-04-2011
		US 2010075996 A1	25-03-2010
		UY 32059 A	26-03-2010
WO 0200661 A1	03-01-2002	AP 1911 A	31-10-2008
		AR 029279 A1	18-06-2003
		AT 323704 T	15-05-2006
		AT 423120 T	15-03-2009
		AU 784297 B2	02-03-2006
		AU 6053801 A	08-01-2002
		BG 107236 A	30-09-2003
		BR 0111561 A	09-09-2003
		CA 2412560 A1	03-01-2002
		CN 1439010 A	27-08-2003
		CZ 20023993 A3	18-02-2004
		DE 60118917 T2	30-11-2006
		DK 1294724 T3	17-07-2006
		DK 1686130 T3	06-04-2009
		DO P2001000200 A	15-02-2003
		EC SP014105 A	25-01-2002
		EE 200200711 A	15-06-2004
		EP 1294724 A1	26-03-2003
		ES 2257410 T3	01-08-2006
		ES 2318605 T3	01-05-2009
		HK 1054930 A1	06-06-2008
		HR 20021000 A2	28-02-2005
		HU 0301114 A2	28-08-2003
		IL 152771 A	15-06-2009
WO 0200661 A1		IS 6606 A	31-10-2002
		JP 4068958 B2	26-03-2008
		JP 2004501922 A	22-01-2004
		MA 26917 A1	20-12-2004
		MX PA03000068 A	25-09-2003
		NO 20026030 A	16-12-2002
		NZ 522364 A	24-09-2004
		OA 12292 A	11-11-2003
		PA 8521101 A1	25-04-2002
		PL 359563 A1	23-08-2004
		PT 1294724 E	31-07-2006

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IB2011/050625

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		SK 17342002 A3	08-06-2004
		SV 2002000506 A	24-10-2002
		TW I243820 B	21-11-2005
		ZA 200210275 A	19-12-2003
WO 2007052125 A2	10-05-2007	AR 058175 A1	23-01-2008
		AU 2006310217 A1	10-05-2007
		CA 2628200 A1	10-05-2007
		CN 101330907 A	24-12-2008
		EA 200800931 A1	30-10-2008
		EC SP088422 A	30-05-2008
		EP 1945186 A2	23-07-2008
		GT 200600474 A	08-06-2007
		JP 4334610 B2	30-09-2009
		JP 2009514847 A	09-04-2009
		KR 20080059427 A	27-06-2008
		MA 30135 B1	02-01-2009
		NL 2000281 C2	07-08-2007
		NL 2000281 A1	03-05-2007
		PE 06932007 A1	11-08-2007
		RS P20080181 A	15-07-2009
		US 2007269511 A1	22-11-2007
		UY 29890 A1	31-05-2007
		ZA 200803115 A	30-09-2009
EP 1681050 A1	19-07-2006	US 2009060995 A1	05-03-2009
WO 2004073695 A1	02-09-2004	AT 410152 T	15-10-2008
		BR PI0407438 A	07-02-2006
		CA 2516327 A1	02-09-2004
		EP 1596841 A1	23-11-2005
		MX PA05008843 A	18-10-2005
		SI 1596841 T1	30-06-2009
		US 2006121106 A1	08-06-2006
US 2007154547 A1	05-07-2007	NONE	
US 2007020335 A1	25-01-2007	NONE	
WO 2009114648 A1	17-09-2009	AU 2009223061 A1	17-09-2009
		CA 2720108 A1	17-09-2009
		CN 102105136 A	22-06-2011
		EP 2262484 A1	22-12-2010
		JP 2011513499 A	28-04-2011
		US 2010015222 A1	21-01-2010

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2011/050625

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 19, 21(completely); 1-18(partially)

A controlled release composition in a form of an orally deliverable tablet comprising a) at least one bioactive agent for veterinary use, (b) a polymer having molecular weight from about 1,000,000 to about 9,000,000 daltons, or a polymer having a viscosity in a range of from about 80,000 to about 120,000 mPa.s, in an amount of about 5% to about 60% of the total weight of the tablet; and (c) at least one disintegrant agent in an amount between about 10% to about 50% of the total weight of the tablet, wherein the bioactive agent is a compound of formulation I.

---

2. claims: 22(completely); 1-18, 20(partially)

A controlled release composition in a form of an orally deliverable tablet comprising a) at least one bioactive agent for veterinary use, (b) a polymer having molecular weight from about 1,000,000 to about 9,000,000 daltons, or a polymer having a viscosity in a range of from about 80,000 to about 120,000 mPa.s, in an amount of about 5% to about 60% of the total weight of the tablet; and (c) at least one disintegrant agent in an amount between about 10% to about 50% of the total weight of the tablet, wherein the bioactive agent is pregabalin.

---

3. claims: 23(completely); 1-18, 20(partially)

A controlled release composition in a form of an orally deliverable tablet comprising a) at least one bioactive agent for veterinary use, (b) a polymer having molecular weight from about 1,000,000 to about 9,000,000 daltons, or a polymer having a viscosity in a range of from about 80,000 to about 120,000 mPa.s, in an amount of about 5% to about 60% of the total weight of the tablet; and (c) at least one disintegrant agent in an amount between about 10% to about 50% of the total weight of the tablet, wherein the bioactive agent is amoxicillin.

---

4. claims: 24(completely); 1-18, 20(partially)

A controlled release composition in a form of an orally deliverable tablet comprising a) at least one bioactive agent for veterinary use, (b) a polymer having molecular weight from about 1,000,000 to about 9,000,000 daltons, or a polymer having a viscosity in a range of from about 80,000 to about 120,000 mPa.s, in an amount of about 5% to about 60% of the total weight of the tablet; and (c) at least one disintegrant agent in an amount between about 10% to about

50% of the total weight of the tablet, wherein the bioactive agent is tramadol.
